Cooley M&A

JUNE 10, 2020

On May 27th, Andy Pasternak, Executive Vice President, Chief Strategy Officer at Horizon Therapeutics and Eric Tokat, a partner in the healthcare practice at Centerview Partners joined Cooley M&A co-chair, Barbara Borden for a discussion of the life sciences M&A market, with a focus on business development. Credibility is key.

M&A 40

M&A Medical Acquisitions Business 40

Global Newswire by Notified: M&A

DECEMBER 7, 2023

According to the new negotiated terms, the Company will acquire 100% of the Target Company and will establish a new wholly-owned Israeli subsidiary, which would in turn merge with and into the Target Company (the “Acquisition”).

Negotiation 45

Negotiation Pharmaceutical Acquisitions Capital 45

Peak Frameworks

SEPTEMBER 18, 2023

company like Tesla, understanding terms like FOB is crucial when negotiating deals and supply contracts overseas. Consider a pharmaceutical giant like Pfizer , which imports raw materials for its drugs. Contractual Implications Negotiating with terms like FOB in mind can lead to more favorable deals.

Private Equity 52

Private Equity Negotiation Transportation Valuation 52

Devensoft

MAY 25, 2023

From identifying the right targets to negotiating deals and integrating teams, there are several critical steps involved in executing a successful restructuring plan. From identifying the right targets to negotiating deals and integrating teams, there are several critical steps involved in executing a successful restructuring plan.

Corporation 52

Corporation Mergers Mergers and Acquisitions Acquisitions 52

Cooley M&A

OCTOBER 24, 2024

While this mantra may help bruised egos on the playground, it’s of no use in M&A disputes. Alexion Pharmaceuticals (Del. September 2024), the Delaware Chancery Courts found buyers liable for failure to comply with negotiated earnout covenants – and in the latter case, awarded the plaintiffs more than $1 billion in damages.

Mergers and Acquisitions 52

Mergers and Acquisitions Mergers Negotiation Sale 52

Cooley M&A

JULY 10, 2017

Similarly, sellers (particularly financial investors) in private M&A transactions are increasingly seeking the right to be able to monetize their rights to contingent consideration by requesting royalty-like earn-out streams and requesting a right to sell the potential future payments to a single third-party purchaser. Private placement.

Securities 52

Securities IT Investors M&A 52

Cooley M&A

OCTOBER 29, 2018

M&A practitioners have long advised boards of directors that the Delaware courts have never found that the events or circumstances in a particular transaction met the contractual standard of having a material adverse effect (or MAE) as defined in a merger or acquisition agreement. We can no longer give this advice. 2018-0300-JTL (Del.

Mergers and Acquisitions 52

Mergers and Acquisitions Mergers Business Pharmaceutical 52

Peak Frameworks

SEPTEMBER 19, 2023

The distinction between them is crucial for understanding a company's obligations, its strategy, and the interplay of interests within its ecosystem. What is a Shareholder? A shareholder is an individual or entity that owns shares or stock in a corporation. Shareholders: are primarily concerned about financial returns.

Corporation 52

Corporation Private Equity Mergers and Acquisitions Corporate Finance 52

Cooley M&A

APRIL 7, 2017

The court agreed with Gilead, based primarily on a review of the parties’ drafting and negotiating history, which was corroborated by the parties’ contemporaneous statements made after the European Commission approved the deal. for a Hematologic Cancer Indication.”

Mergers and Acquisitions 40

Mergers and Acquisitions Negotiation Pharmaceutical IT 40

Devensoft

AUGUST 24, 2023

Mastering Operations, Cross-Selling, and Cost Efficiencies for Maximizing Value from Integrated Ventures The Power of Synergy and Value Creation Amidst the dynamic and fiercely competitive modern business arena, corporations continually strive to secure a distinct market advantage while fostering expansion. Get a copy to-go.

Business 52

Business Collaboration Mergers and Acquisitions Management 52

Cooley M&A

JANUARY 20, 2022

General trends in life sciences M&A. While 2020’s M&A landscape was characterized by whiplash volatility from choppy deal activity in the first half of the year to a surge in volume in the second half, that momentum accelerated in 2021, with no signs of slowing down heading into 2022. driven assets.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Cooley M&A

FEBRUARY 15, 2017

So far this year, deal parties are approaching M&A with cautious optimism. Over the next few days, we will run a series of Cooley M&A blog posts with some brief observations that offer some M&A highlights over the past year and our thoughts for the year to come. Read more from our 2017 M&A Trends Series.

M&A 40

M&A IPO Pharmaceutical Valuation 40

MergersCorp M&A International

NOVEMBER 16, 2024

His presidency brought with it a unique set of policies and attitudes that would directly influence the realm of mergers and acquisitions (M&A). This post will delve into how Trump’s administration impacted M&A activities, examining both the opportunities created and the challenges faced during his tenure.

Mergers and Acquisitions 52

Mergers and Acquisitions Mergers Acquisitions M&A 52

Cooley M&A

JANUARY 21, 2022

One year into his administration, President Joe Biden has made clear that aggressive competition policy is on the agenda. With a team of progressives filling leadership roles at the Federal Trade Commission and in the Antitrust Division of the US Department of Justice, companies are able to predict what the next several years may look like.

Mergers and Acquisitions 40

Mergers and Acquisitions Mergers Pharmaceutical IT 40

Cooley M&A

JANUARY 18, 2017

Transition to a Trump Administration is top of the agenda. History teaches that we may also see nominees from among Republican staff on House or Senate committees with oversight over the DOJ and FTC, lawyers connected to senior administration officials not well-known by the antitrust community, or business executives with no antitrust expertise.

Mergers and Acquisitions 40

Mergers and Acquisitions Pharmaceutical Mergers Investment 40